Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stimulants01:29

Stimulants

1.4K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.4K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.3K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.3K
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

229
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
229
Drug Dependence01:17

Drug Dependence

2.0K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
2.0K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

251
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
251

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State Actions on Tobacco Prevention and Cessation.

NCSL legisbrief·2018
Same author

Regulating Hemp and Cannabis-Based Products.

NCSL legisbrief·2017
Same author

Addressing Depression.

NCSL legisbrief·2016
Same author

Benefits and Limits of Abuse-Deterrent Painkillers.

NCSL legisbrief·2016
Same author

Treating hepatitis C.

NCSL legisbrief·2014
Same author

Public health department accreditation.

NCSL legisbrief·2013

Related Experiment Video

Updated: Apr 19, 2026

Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
08:39

Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies

Published on: August 25, 2018

26.8K

Electronic cigarettes and alternative nicotine products.

Karmen Hanson1

  • 1NCSL--Denver, US

NCSL Legisbrief
|December 18, 2014
PubMed
Summary

Currently, the U.S. Food and Drug Administration (FDA) does not regulate electronic cigarettes. State governments are implementing diverse regulations for these products due to varying ingredients and designs.

Area of Science:

  • Public Health
  • Regulatory Science
  • Consumer Product Safety

Background:

  • Electronic cigarettes (e-cigarettes) and vaporizers represent a rapidly evolving product category.
  • There is a lack of federal regulatory oversight by the U.S. Food and Drug Administration (FDA) for e-cigarettes.
  • Significant variability exists in the ingredients, device designs, and manufacturing processes of e-cigarettes and vaporizers.

Purpose of the Study:

  • To examine the current regulatory landscape of electronic cigarettes in the United States.
  • To highlight the absence of federal regulation and the diverse state-level actions.
  • To inform stakeholders about the complexities of e-cigarette regulation.

Main Methods:

  • Review of existing federal regulations pertaining to electronic nicotine delivery systems.

More Related Videos

A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
09:30

A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol

Published on: January 18, 2018

9.1K
Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
10:44

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System

Published on: May 24, 2017

12.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
08:39

Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies

Published on: August 25, 2018

26.8K
A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
09:30

A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol

Published on: January 18, 2018

9.1K
Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
10:44

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System

Published on: May 24, 2017

12.3K
  • Analysis of legislative actions taken by individual states to regulate e-cigarettes.
  • Comparative assessment of state-specific regulatory approaches.

    • Main Results:

    • The U.S. Food and Drug Administration (FDA) has not yet established comprehensive federal regulations for electronic cigarettes.
    • A patchwork of state-level regulations is emerging, addressing aspects such as sales, marketing, and product standards.
    • Disparities in state regulations create a complex and inconsistent environment for e-cigarette oversight.

    Conclusions:

    • The lack of federal FDA regulation necessitates state-driven initiatives to address public health concerns associated with e-cigarettes.
    • The varied state regulations underscore the need for a more unified and robust regulatory framework.
    • Further research and policy development are crucial to ensure the safety and appropriate oversight of electronic cigarettes and vaporizers.